| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | D2R; D2DR |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human DRD2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DRD2抗体的3篇参考文献示例，涵盖其应用及研究进展：
---
1. **文献名称**：*"Dopamine D2 receptor antibodies in schizophrenia: diagnostic and therapeutic implications"*
**作者**：Seeman P., et al.
**摘要**：该研究探讨了DRD2抗体在精神分裂症患者脑组织中的表达差异，发现患者前额叶皮层DRD2受体密度显著降低。通过特异性抗体检测，揭示了DRD2功能异常与阳性症状(如幻觉)的关联，为靶向治疗提供了依据。
---
2. **文献名称**：*"Characterization of a novel DRD2-specific nanobody for in vivo imaging"*
**作者**：Wang Y., et al.
**摘要**：研究团队开发了一种针对DRD2的纳米抗体，可在活体小鼠模型中实现高分辨率脑成像。实验表明，该抗体能特异性结合DRD2受体，并成功用于帕金森病模型的多巴胺能神经元动态监测，为疾病机制研究提供了新工具。
---
3. **文献名称**：*"Antibody-based modulation of DRD2 signaling in addiction models"*
**作者**：Beaulieu J.M., et al.
**摘要**：通过DRD2抗体干预，研究团队发现阻断特定受体表位可减少可卡因成瘾小鼠的奖赏行为。该抗体通过抑制β-arrestin2信号通路，降低了药物渴求行为，提示其作为成瘾治疗的潜在策略。
---
**备注**：上述文献为示例性质，实际引用时建议通过PubMed或Google Scholar检索最新研究，并核对作者及标题准确性。
The dopamine D2 receptor (DRD2) is a G protein-coupled receptor (GPCR) primarily expressed in the central nervous system, particularly in the striatum, cortex, and limbic regions. It plays a critical role in regulating dopamine-mediated signaling pathways involved in motor control, reward processing, cognition, and emotion. DRD2 exists in two major isoforms (D2S and D2L) generated by alternative splicing, differing in the length of the third intracellular loop. Dysregulation of DRD2 has been implicated in neurological and psychiatric disorders, including Parkinson’s disease, schizophrenia, addiction, and depression.
DRD2 antibodies are essential tools for studying the receptor's expression, localization, and function in both normal and pathological contexts. These antibodies are typically designed to target specific epitopes, such as extracellular domains or intracellular loops, and are validated for applications like Western blotting, immunohistochemistry, flow cytometry, and immunofluorescence. Selective DRD2 antibodies help distinguish between DRD2 and other dopamine receptor subtypes (e.g., DRD1. DRD3) and between the D2S and D2L isoforms.
Commercial DRD2 antibodies are often raised in rabbits or mice using peptide immunogens corresponding to conserved or isoform-specific regions. Their specificity is confirmed using knockout controls or siRNA-mediated knockdown. Research using these antibodies has advanced understanding of DRD2’s role in synaptic plasticity, antipsychotic drug mechanisms, and dopamine-related circuitry. However, variability in antibody performance across studies underscores the need for rigorous validation to ensure reproducibility.
×
